Rothschild Investment LLC’s Sage Therapeutics SAGE Stock Holding History

Rothschild Investment LLC’s Portfolio SAGE Stock Details SAGE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q3	–	Sell	-205	Closed	-$1.87K	–	3232
2025 Q2	$1.87K	Sell	205 -225	-52%	-$1.66K	﹤0.01%	2130
2025 Q1	$3.42K	Buy	430 +270	+169%	+$1.98K	﹤0.01%	1616
2024 Q4	$869	Buy	160 +130	+433%	+$795	﹤0.01%	2291
2024 Q3	$217	Sell	30 -240	-89%	-$2.2K	﹤0.01%	2701
2024 Q2	$2.93K	Buy	270 +15	+6%	+$192	﹤0.01%	1291
2024 Q1	$4.78K	Buy	255 +5	+2%	+$115	﹤0.01%	1140
2023 Q4	$5.42K	Buy	+250	New	+$4.95K	﹤0.01%	1070

Other funds holding SAGE

DekaBank Deutsche Girozentrale Frankfurt, Germany $60.6B AUM 23.27% 1-Year Est. Return

Osaic Holdings Scottsdale, Arizona $68.3B AUM 20.5% 1-Year Est. Return

IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return

HNB

Huntington National Bank Columbus, Ohio $18.1B AUM 24.69% 1-Year Est. Return

Rothschild Investment LLC's SAGE Position: Q3 2025 in Review

Rothschild Investment LLC sold out of Sage Therapeutics (SAGE) in Q3 2025, closing a stake of 205 shares — an estimated $1.87K sold.

Rothschild Investment LLC first reported a position in SAGE in Q4 2023 and held it in 7 quarters. The position peaked at $5.42K in Q4 2023. 5 funds tracked by Wall St. Rank hold SAGE as of Q3 2025.

Rothschild Investment LLC reported no remaining Sage Therapeutics position as of Q3 2025 after selling out during the quarter.
Rothschild Investment LLC sold 205 Sage Therapeutics shares in Q3 2025, an estimated $1.87K.
Rothschild Investment LLC first reported a position in Sage Therapeutics in Q4 2023 and held it in 7 quarters.
Rothschild Investment LLC's Sage Therapeutics position peaked at $5.42K in Q4 2023.
5 funds tracked by Wall St. Rank held Sage Therapeutics as of Q3 2025.

Based on Rothschild Investment LLC's 13F filing for Q3 2025, filed 7 Nov 2025.